Why is Teva Pharma stock surging today?
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Medincell SA (MEDCL)
The Medincell share price today is 26.76, view EPA MEDCL stock exchange data. Track the latest Medincell share price with real-time updates on MEDCL stock performance including market cap, day range, 52-week range and dividend yield. Access MEDCL charts, earnings dates and analyst estimates to support your investment decisions.
26.76
+0.18(+0.68%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
26.10
26.96
52 wk Range
19.69
39.68
MEDCL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
26.1026.96
52 wk Range
19.6939.68
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MEDCL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
35.91
Upside
+34.20%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Liquid assets exceed short term obligations
Medincell SA receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Why is Teva Pharma stock surging today?
- Investing.com
- Medincell SA receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Why is Medincell stock plunging today?- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Analyst Ratings
9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 35.91
(+34.20% Upside)
Earnings
Latest Release
02-09-2026
EPS / Forecast
-- / -0.14
Revenue / Forecast
-- / 6.8M
Compare MEDCL to Peers and Sector
Metrics to compare | MEDCL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMEDCLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −30.5x | 17.5x | −0.3x | |
PEG Ratio | 0.61 | 0.08 | 0.00 | |
Price/Book | 311.5x | 2.2x | 2.6x | |
Price / LTM Sales | 39.3x | 2.2x | 2.9x | |
Upside (Analyst Target) | 33.3% | 66.7% | 63.9% | |
Fair Value Upside | Unlock | 6.2% | 9.4% | Unlock |
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of post-operative pain and inflammation. In addition, the company engages in the development of products in preclinical stage, including mdc-WWM for contraception; mdc-STM for the treatment of malaria; and mdc-AbbVie-1. It has strategic collaborations with TEVA, AIC, ABBVIE, Unitaid, and Gates Foundation. The company was incorporated in 2003 and is headquartered in Jacou, France.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Medincell (MEDCL) Share Price Today?
The Medincell share price today is 26.76.
What is the current Medincell (MEDCL) share price and day range?
As of 14-10-2026, the Medincell share price is 26.76, with a previous close of 26.58. The share price has ranged from 26.10 to 26.96 today, while the 52-week range spans from 19.69 to 39.68.
What Is the Medincell Market Cap?
As of today, Medincell market cap is 947.35M.
What Is the Medincell (MEDCL) Share Price Target?
The average 12-month share price target for Medincell is 35.91, with a high estimate of 40 and a low estimate of 31. 9 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +34.20% Upside potential.
What Is Medincell's Earnings Per Share (TTM)?
The Medincell EPS (TTM) is -0.94.
When Is the Next Medincell Earnings Date?
Medincell will release its next earnings report on 08-12-2026.
From a Technical Analysis Perspective, Is MEDCL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Medincell Trade On?
Medincell is listed and trades on the Paris Stock Exchange.
What Is the Stock Symbol for Medincell?
The stock symbol for Medincell is "MEDCL."
How Many Times Has Medincell Stock Split?
Medincell has split 0 times.
How Many Employees Does Medincell Have?
Medincell has 141 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.